SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
(Exact name of registrant as specified in charter)
(Address of principal executive offices) (Zip code)
(Name and address of agent for service)
New Investments by the Fund
Additions to Existing Investments
Positions Entirely Disposed of
Reductions in Existing Investments
Net asset value returns
|
1 year
|
5 years
|
10 years
|
The Swiss Helvetia Fund, Inc.
|
16.92%
|
9.52%
|
6.09%
|
Market price returns
|
|||
The Swiss Helvetia Fund, Inc.
|
15.48%
|
9.76%
|
5.73%
|
Index returns
|
|||
Swiss Performance Index
|
16.54%
|
11.70%
|
6.99%
|
Share price as of 12/31/2023
|
|||
Net asset value
|
|
||
Market price
|
|
Schedule of Investments by Industry |
December 31, 2023
|
Percent
|
|||||||||||
No. of
|
of Net
|
||||||||||
Shares
|
Security
|
Value
|
Assets
|
||||||||
Common Stock — 97.78%
|
|||||||||||
Advertising — 1.15%
|
|||||||||||
21,000
|
DKSH Holding AG
|
$
|
1,457,138
|
1.15
|
%
|
||||||
An international
|
|||||||||||
marketing and services
|
|||||||||||
group. The company offers
|
|||||||||||
a comprehensive package
|
|||||||||||
of services that includes
|
|||||||||||
organizing and running
|
|||||||||||
the entire value chain
|
|||||||||||
for any product.
|
|||||||||||
(Cost $1,461,589)
|
|||||||||||
1,457,138
|
1.15
|
%
|
|||||||||
Banks — 3.03%
|
|||||||||||
425
|
St Galler Kantonalbank AG
|
248,188
|
0.19
|
%
|
|||||||
Offers retail and
|
|||||||||||
commercial banking
|
|||||||||||
as well as private and
|
|||||||||||
institutional banking.
|
|||||||||||
Also provides asset
|
|||||||||||
management and financial
|
|||||||||||
planning services.
|
|||||||||||
(Cost $200,119)
|
|||||||||||
116,000
|
UBS Group AG
|
3,597,220
|
2.84
|
%
|
|||||||
Provides retail banking,
|
|||||||||||
corporate and institutional
|
|||||||||||
banking, wealth
|
|||||||||||
management, asset
|
|||||||||||
management and
|
|||||||||||
investment banking.
|
|||||||||||
(Cost $1,582,000)
|
|||||||||||
3,845,408
|
3.03
|
%
|
|||||||||
Biotechnology — 2.28%
|
|||||||||||
10,801
|
Bachem Holding AG
|
|
834,153
|
0.66
|
%
|
||||||
Specializes in the
|
|||||||||||
development and
|
|||||||||||
manufacture of peptides
|
|||||||||||
and oligonucleotides.
|
|||||||||||
The company provides
|
|||||||||||
products for research,
|
|||||||||||
clinical development and
|
|||||||||||
commercial application to
|
|||||||||||
pharmaceutical and
|
|||||||||||
biotechnology companies.
|
|||||||||||
(Cost $827,767)
|
|||||||||||
41,308
|
Idorsia Ltd.1
|
103,755
|
0.08
|
%
|
|||||||
Researches, develops,
|
|||||||||||
and manufactures
|
|||||||||||
pharmaceutical, biological,
|
|||||||||||
and diagnostic products.
|
|||||||||||
(Cost $1,141,327)
|
|||||||||||
4,650
|
Lonza Group AG
|
1,954,143
|
1.54
|
%
|
|||||||
Produces organic fine
|
|||||||||||
chemicals, biocides, active
|
|||||||||||
ingredients, and
|
|||||||||||
biotechnology products.
|
|||||||||||
(Cost $2,620,486)
|
|||||||||||
2,892,051
|
2.28
|
%
|
|||||||||
Building Materials — 2.96%
|
|||||||||||
820
|
Forbo Holding AG
|
1,026,888
|
0.81
|
%
|
|||||||
Produces floor coverings,
|
|||||||||||
adhesives and belts for
|
|||||||||||
conveying and
|
|||||||||||
power transmission.
|
|||||||||||
(Cost $1,292,481)
|
See Notes to Financial Statements.
Schedule of Investments by Industry |
December 31, 2023
|
(continued) |
Percent
|
|||||||||||
No. of
|
of Net
|
||||||||||
Shares
|
Security
|
Value
|
Assets
|
||||||||
Common Stock — (continued)
|
|||||||||||
Building Materials — (continued)
|
|||||||||||
8,400
|
Sika AG
|
$
|
2,731,634
|
2.15
|
%
|
||||||
Manufactures construction
|
|||||||||||
materials, producing
|
|||||||||||
concrete and mixtures,
|
|||||||||||
mortar, sealants and
|
|||||||||||
adhesives, tooling resins,
|
|||||||||||
anti-static industrial
|
|||||||||||
flooring, and acoustic
|
|||||||||||
materials. The company
|
|||||||||||
serves customers worldwide.
|
|||||||||||
(Cost $1,566,770)
|
|||||||||||
3,758,522
|
2.96
|
%
|
|||||||||
Chemicals — 1.34%
|
|||||||||||
410
|
Givaudan SA
|
1,697,190
|
1.34
|
%
|
|||||||
Manufactures and markets
|
|||||||||||
fragrances and flavors
|
|||||||||||
from natural and synthetic
|
|||||||||||
ingredients. The Company
|
|||||||||||
sells its products to
|
|||||||||||
manufactures of perfumes,
|
|||||||||||
beverages, prepared foods,
|
|||||||||||
and consumer goods.
|
|||||||||||
(Cost $1,239,873)
|
|||||||||||
1,697,190
|
1.34
|
%
|
|||||||||
Computers — 1.68%
|
|||||||||||
18,000
|
Logitech International SA
|
1,705,792
|
1.34
|
%
|
|||||||
Engages in the
|
|||||||||||
development and
|
|||||||||||
marketing of hardware and
|
|||||||||||
software products that
|
|||||||||||
enable or enhance digital
|
|||||||||||
navigation, music and video
|
|||||||||||
entertainment, gaming,
|
|||||||||||
social networking and audio
|
|||||||||||
and video communication.
|
|||||||||||
(Cost $244,048)
|
|||||||||||
22,000
|
SoftwareONE Holding AG
|
|
428,682
|
0.34
|
%
|
||||||
Provides IT services. The
|
|||||||||||
Company offers cloud
|
|||||||||||
computing, portfolio
|
|||||||||||
management, procurement,
|
|||||||||||
unified communication,
|
|||||||||||
and other related solutions.
|
|||||||||||
(Cost $400,813)
|
|||||||||||
2,134,474
|
1.68
|
%
|
|||||||||
Diversified Financial Services — 3.27%
|
|||||||||||
27,000
|
Julius Baer Group Ltd.
|
1,512,565
|
1.19
|
%
|
|||||||
Provides private banking
|
|||||||||||
services. The company
|
|||||||||||
advises on wealth
|
|||||||||||
management, financial
|
|||||||||||
planning and investments;
|
|||||||||||
offers mortgage and other
|
|||||||||||
lending, foreign exchange,
|
|||||||||||
securities trading, custody
|
|||||||||||
and execution services.
|
|||||||||||
(Cost $1,314,961)
|
|||||||||||
6,000
|
Swissquote Group
|
||||||||||
Holding SA
|
1,458,563
|
1.15
|
%
|
||||||||
Through its subsidiaries,
|
|||||||||||
offers online financial
|
|||||||||||
services. The company
|
|||||||||||
operates an online trading
|
|||||||||||
system which offers
|
|||||||||||
customers real-time
|
|||||||||||
securities quotes on the
|
|||||||||||
Swiss Stock Exchange.
|
|||||||||||
(Cost $581,470)
|
See Notes to Financial Statements.
Schedule of Investments by Industry |
December 31, 2023
|
(continued) |
Percent
|
|||||||||||
No. of
|
of Net
|
||||||||||
Shares
|
Security
|
Value
|
Assets
|
||||||||
Common Stock — (continued)
|
|||||||||||
Diversified Financial Services — (continued)
|
|||||||||||
10,030
|
VZ Holding AG
|
$
|
1,170,256
|
0.93
|
%
|
||||||
Provides independent
|
|||||||||||
financial advice to private
|
|||||||||||
individuals and companies.
|
|||||||||||
The company consults on
|
|||||||||||
investment, tax and
|
|||||||||||
inheritance planning and
|
|||||||||||
provides advice regarding
|
|||||||||||
insurance products
|
|||||||||||
and coverage.
|
|||||||||||
(Cost $327,269)
|
|||||||||||
4,141,384
|
3.27
|
%
|
|||||||||
Electric — 1.54%
|
|||||||||||
11,000
|
BKW AG
|
1,953,900
|
1.54
|
%
|
|||||||
Provides energy supply
|
|||||||||||
services. The company
|
|||||||||||
focuses on the production,
|
|||||||||||
transportation, trading and
|
|||||||||||
sale of energy. In addition
|
|||||||||||
to energy supply, the
|
|||||||||||
company also develops,
|
|||||||||||
implements and operates
|
|||||||||||
energy solutions for
|
|||||||||||
its clients.
|
|||||||||||
(Cost $737,667)
|
|||||||||||
1,953,900
|
1.54
|
%
|
|||||||||
Electronic Components & Equipment — 2.73%
|
|||||||||||
35,500
|
ABB Ltd.
|
1,573,278
|
1.24
|
%
|
|||||||
Provides power and
|
|||||||||||
automation technologies.
|
|||||||||||
The company operates
|
|||||||||||
under segments that
|
|||||||||||
include power products,
|
|||||||||||
power systems, automation
|
|||||||||||
products, process
|
|||||||||||
automation, and robotics.
|
|||||||||||
(Cost $716,888)
|
|||||||||||
2,000
|
Comet Holding AG
|
|
630,191
|
0.50
|
%
|
||||||
Develops, produces, and
|
|||||||||||
distributes components
|
|||||||||||
and systems for x-ray tubes,
|
|||||||||||
vacuum condensers, and
|
|||||||||||
radio frequency, as well as
|
|||||||||||
other medical products.
|
|||||||||||
(Cost $402,700)
|
|||||||||||
100,000
|
R&S Group Holding AG1
|
1,259,431
|
0.99
|
%
|
|||||||
Manufactures small and
|
|||||||||||
medium power and
|
|||||||||||
distribution transformers
|
|||||||||||
and other components in
|
|||||||||||
the utility, infrastructure,
|
|||||||||||
and industrial sectors.
|
|||||||||||
(Cost $1,137,204)
|
|||||||||||
3,462,900
|
2.73
|
%
|
|||||||||
Food — 20.70%
|
|||||||||||
1,234,586
|
Aryzta AG1
|
2,276,573
|
1.79
|
%
|
|||||||
Produces and retails
|
|||||||||||
specialty bakery products.
|
|||||||||||
The Company produces
|
|||||||||||
French breads, pastries,
|
|||||||||||
continental breads,
|
|||||||||||
confections, artisan breads,
|
|||||||||||
homestyle lunches,
|
|||||||||||
viennoiserie, patisserie,
|
|||||||||||
cookies, pizza, appetizers,
|
|||||||||||
and sweet baked goods.
|
|||||||||||
(Cost $1,266,401)
|
|||||||||||
900
|
Barry Callebaut AG
|
1,517,376
|
1.20
|
%
|
|||||||
Manufactures cocoa and
|
|||||||||||
chocolate products. The
|
|||||||||||
Company markets to
|
|||||||||||
industrial food
|
|||||||||||
manufacturers, chocolatiers,
|
|||||||||||
pastry chefs, bakers, and
|
|||||||||||
retailers globally.
|
|||||||||||
(Cost $1,669,891)
|
See Notes to Financial Statements.
Schedule of Investments by Industry |
December 31, 2023
|
(continued) |
Percent
|
|||||||||||
No. of
|
of Net
|
||||||||||
Shares
|
Security
|
Value
|
Assets
|
||||||||
Common Stock — (continued)
|
|||||||||||
Food — (continued)
|
|||||||||||
193,837
|
Nestle SA
|
$
|
22,457,133
|
17.71
|
%
|
||||||
One of the world’s largest
|
|||||||||||
food and beverage
|
|||||||||||
processing companies.
|
|||||||||||
(Cost $12,557,687)
|
|||||||||||
26,251,082
|
20.70
|
%
|
|||||||||
Health Care — 2.34%
|
|||||||||||
70,000
|
Sandoz Group AG1
|
2,250,579
|
1.77
|
%
|
|||||||
Manufactures and
|
|||||||||||
distributes generic and
|
|||||||||||
biosimilar medicines for the
|
|||||||||||
treatment of patients with
|
|||||||||||
diseases such as cancer,
|
|||||||||||
diabetes, and arthritis.
|
|||||||||||
(Cost $1,574,032)
|
|||||||||||
2,000
|
Ypsomed Holding AG
|
720,014
|
0.57
|
%
|
|||||||
Develops and manufactures
|
|||||||||||
custom-made injection
|
|||||||||||
systems for pharmaceutical
|
|||||||||||
and bio-technology
|
|||||||||||
companies.
|
|||||||||||
(Cost $583,146)
|
|||||||||||
2,970,593
|
2.34
|
%
|
|||||||||
Healthcare-Products — 7.30%
|
|||||||||||
34,000
|
Alcon, Inc.
|
2,651,648
|
2.09
|
%
|
|||||||
Manufactures eye care
|
|||||||||||
products. The company
|
|||||||||||
produces and markets
|
|||||||||||
vitreoretinal and cataract
|
|||||||||||
surgery, contact lenses,
|
|||||||||||
and refractive
|
|||||||||||
technology products.
|
|||||||||||
(Cost $2,296,818)
|
|||||||||||
125,416
|
Eyesense AG, Series A1,2,3
|
|
1,490
|
0.00
|
%
|
||||||
A spin-out from Ciba Vision
|
|||||||||||
AG. Develops novel
|
|||||||||||
ophthalmic self- diagnostic
|
|||||||||||
systems for glucose
|
|||||||||||
monitoring of diabetes
|
|||||||||||
patients.
|
|||||||||||
(Cost $3,007,048)
|
|||||||||||
8,500
|
Medacta Group SA
|
1,268,461
|
1.00
|
%
|
|||||||
Produces and distributes
|
|||||||||||
medical devices. The
|
|||||||||||
company develops,
|
|||||||||||
manufactures, and
|
|||||||||||
distributes orthopedic
|
|||||||||||
and neurosurgical
|
|||||||||||
medical devices.
|
|||||||||||
(Cost $940,840)
|
|||||||||||
6,848
|
SKAN Group AG
|
657,421
|
0.52
|
%
|
|||||||
Provides health care
|
|||||||||||
supplies. The Company
|
|||||||||||
offers isolators,
|
|||||||||||
cleanroom devices, and
|
|||||||||||
decontamination processes
|
|||||||||||
for the aseptic production
|
|||||||||||
of the biopharmaceutical
|
|||||||||||
products.
|
|||||||||||
(Cost $530,142)
|
|||||||||||
3,000
|
Sonova Holding AG
|
978,079
|
0.77
|
%
|
|||||||
Designs and produces
|
|||||||||||
wireless analog and digital
|
|||||||||||
in-the-ear and behind-the-ear
|
|||||||||||
hearing aids and
|
|||||||||||
miniaturized voice
|
|||||||||||
communications systems.
|
|||||||||||
(Cost $457,261)
|
See Notes to Financial Statements.
Schedule of Investments by Industry |
December 31, 2023
|
(continued) |
Percent
|
|||||||||||
No. of
|
of Net
|
||||||||||
Shares
|
Security
|
Value
|
Assets
|
||||||||
Common Stock — (continued)
|
|||||||||||
Healthcare-Products — (continued)
|
|||||||||||
221,085
|
Spineart SA1,2,3
|
$
|
1,339,670
|
1.06
|
%
|
||||||
Designs and markets an
|
|||||||||||
innovative full range of
|
|||||||||||
spine products, including
|
|||||||||||
fusion and motion
|
|||||||||||
preservation devices,
|
|||||||||||
focusing on easy to implant
|
|||||||||||
high-end products to
|
|||||||||||
simplify the surgical act.
|
|||||||||||
(Cost $1,554,486)
|
|||||||||||
5,800
|
Tecan Group AG
|
2,366,447
|
1.86
|
%
|
|||||||
Manufactures and
|
|||||||||||
distributes laboratory
|
|||||||||||
automation components
|
|||||||||||
and systems. The products
|
|||||||||||
are mainly used by research
|
|||||||||||
and diagnostic laboratories.
|
|||||||||||
(Cost $815,502)
|
|||||||||||
9,263,216
|
7.30
|
%
|
|||||||||
Healthcare-Services — 0.77%
|
|||||||||||
11,300
|
Galenica AG
|
976,742
|
0.77
|
%
|
|||||||
Retails pharmaceutical
|
|||||||||||
products, and services
|
|||||||||||
customers in Switzerland.
|
|||||||||||
The Company offers health,
|
|||||||||||
beauty, and related
|
|||||||||||
products and services.
|
|||||||||||
(Cost $902,693)
|
|||||||||||
976,742
|
0.77
|
%
|
|||||||||
Industrials — 1.38%
|
|||||||||||
1,252
|
Belimo Holding AG1
|
689,928
|
0.55
|
%
|
|||||||
Manufactures heating,
|
|||||||||||
ventilation and air
|
|||||||||||
conditioning equipment.
|
|||||||||||
(Cost $144,479)
|
|||||||||||
234,000
|
OC Oerlikon Corp. AG
|
|
1,055,384
|
0.83
|
%
|
||||||
Manufactures industrial
|
|||||||||||
equipment. The Company
|
|||||||||||
produces protective
|
|||||||||||
coatings for precision
|
|||||||||||
tools and components,
|
|||||||||||
equipment for textile
|
|||||||||||
production, and propulsion
|
|||||||||||
technology drive systems.
|
|||||||||||
(Cost $2,574,223)
|
|||||||||||
1,745,312
|
1.38
|
%
|
|||||||||
Insurance — 8.32%
|
|||||||||||
12,000
|
Baloise Holding AG
|
1,879,166
|
1.48
|
%
|
|||||||
Offers group and individual
|
|||||||||||
life, health, accident,
|
|||||||||||
liability property, and
|
|||||||||||
transportation insurance
|
|||||||||||
to customers in Europe.
|
|||||||||||
The Company also offers
|
|||||||||||
private banking and asset
|
|||||||||||
management services.
|
|||||||||||
(Cost $1,807,178)
|
|||||||||||
6,700
|
Helvetia Holding AG
|
922,628
|
0.73
|
%
|
|||||||
Provides a broad range of
|
|||||||||||
life, casualty, liability,
|
|||||||||||
accident and transportation
|
|||||||||||
insurance in Switzerland
|
|||||||||||
and in other European
|
|||||||||||
countries. The Company
|
|||||||||||
insures individuals, property
|
|||||||||||
such as vehicles and
|
|||||||||||
buildings, and consumer
|
|||||||||||
goods and personal
|
|||||||||||
belongings.
|
|||||||||||
(Cost $579,944)
|
|||||||||||
3,263
|
Swiss Life Holding AG
|
2,264,115
|
1.79
|
%
|
|||||||
Provides life insurance
|
|||||||||||
and institutional
|
|||||||||||
investment management.
|
|||||||||||
(Cost $785,435)
|
See Notes to Financial Statements.
Schedule of Investments by Industry |
December 31, 2023
|
(continued) |
Percent
|
|||||||||||
No. of
|
of Net
|
||||||||||
Shares
|
Security
|
Value
|
Assets
|
||||||||
Common Stock — (continued)
|
|||||||||||
Insurance — (continued)
|
|||||||||||
10,500
|
Zurich Insurance
|
||||||||||
Group AG
|
$
|
5,484,227
|
4.32
|
%
|
|||||||
Provides insurance-based
|
|||||||||||
financial services. The
|
|||||||||||
company offers general
|
|||||||||||
and life insurance products
|
|||||||||||
and services for individuals,
|
|||||||||||
small businesses, commercial
|
|||||||||||
enterprises, mid-sized and
|
|||||||||||
large corporations, and
|
|||||||||||
multinational companies.
|
|||||||||||
(Cost $3,383,755)
|
|||||||||||
10,550,136
|
8.32
|
%
|
|||||||||
Machinery-Diversified — 0.76%
|
|||||||||||
31,000
|
Accelleron Industries AG
|
967,219
|
0.76
|
%
|
|||||||
Develops, produces, and
|
|||||||||||
services turbochargers
|
|||||||||||
and large turbocharging
|
|||||||||||
components. The Company
|
|||||||||||
offers turbocharging
|
|||||||||||
technologies and
|
|||||||||||
optimization solutions for
|
|||||||||||
engines thereby reducing
|
|||||||||||
the environmental impact
|
|||||||||||
with less fuel emissions.
|
|||||||||||
(Cost $562,702)
|
|||||||||||
967,219
|
0.76
|
%
|
|||||||||
Metal Fabricate/Hardware — 1.07%
|
|||||||||||
11,000
|
SFS Group AG
|
1,361,849
|
1.07
|
%
|
|||||||
Provides automotive
|
|||||||||||
products, building and
|
|||||||||||
electronic components, flat
|
|||||||||||
roofing and solar fastening
|
|||||||||||
systems. The company
|
|||||||||||
operates production
|
|||||||||||
facilities in Asia, Europe
|
|||||||||||
and North America.
|
|||||||||||
(Cost $719,463)
|
|||||||||||
1,361,849
|
1.07
|
%
|
|||||||||
Packaging & Containers — 1.63%
|
|||||||||||
90,000
|
SIG Combibloc Group AG
|
|
2,069,150
|
1.63
|
%
|
||||||
The company, through its
|
|||||||||||
subsidiaries, manufactures
|
|||||||||||
and produces bottling
|
|||||||||||
machines and systems for
|
|||||||||||
the food and beverage
|
|||||||||||
industries. The company
|
|||||||||||
serves customers
|
|||||||||||
worldwide.
|
|||||||||||
(Cost $1,234,854)
|
|||||||||||
2,069,150
|
1.63
|
%
|
|||||||||
Pharmaceuticals — 21.66%
|
|||||||||||
142,229
|
Novartis AG
|
14,342,037
|
11.31
|
%
|
|||||||
One of the leading
|
|||||||||||
manufacturers of branded
|
|||||||||||
and generic
|
|||||||||||
pharmaceutical products.
|
|||||||||||
(Cost $6,989,680)
|
|||||||||||
45,177
|
Roche Holding AG
|
13,123,955
|
10.35
|
%
|
|||||||
Develops and
|
|||||||||||
manufactures
|
|||||||||||
pharmaceutical and
|
|||||||||||
diagnostic products.
|
|||||||||||
Produces prescription
|
|||||||||||
drugs to treat cardiovascular,
|
|||||||||||
infectious and autoimmune
|
|||||||||||
diseases and for other
|
|||||||||||
areas including dermatology
|
|||||||||||
and oncology.
|
|||||||||||
(Cost $8,109,729)
|
|||||||||||
27,465,992
|
21.66
|
%
|
See Notes to Financial Statements.
Schedule of Investments by Industry |
December 31, 2023
|
(continued) |
Percent
|
|||||||||||
No. of
|
of Net
|
||||||||||
Shares
|
Security
|
Value
|
Assets
|
||||||||
Common Stock — (continued)
|
|||||||||||
Private Equity — 2.79%
|
|||||||||||
2,450
|
Partners Group
|
||||||||||
Holding AG
|
$
|
3,530,981
|
2.79
|
%
|
|||||||
A global private markets
|
|||||||||||
investment management
|
|||||||||||
firm with investment
|
|||||||||||
programs under
|
|||||||||||
management in private
|
|||||||||||
equity, private real estate,
|
|||||||||||
private infrastructure and
|
|||||||||||
private debt. The firm
|
|||||||||||
manages a broad range of
|
|||||||||||
customized portfolios for
|
|||||||||||
an international clientele of
|
|||||||||||
institutional investors.
|
|||||||||||
Partners Group is
|
|||||||||||
headquartered in Zug,
|
|||||||||||
Switzerland.
|
|||||||||||
(Cost $1,917,144)
|
|||||||||||
3,530,981
|
2.79
|
%
|
|||||||||
Retail — 6.42%
|
|||||||||||
44,000
|
Cie Financiere
|
||||||||||
Richemont SA
|
6,051,209
|
4.77
|
%
|
||||||||
Manufactures and retails
|
|||||||||||
luxury goods. Produces
|
|||||||||||
jewelry, watches, leather
|
|||||||||||
goods, writing instruments
|
|||||||||||
and men’s and
|
|||||||||||
women’s wear.
|
|||||||||||
(Cost $3,421,020)
|
|||||||||||
40,000
|
Swatch Group AG –
|
||||||||||
Registered Shares
|
|
2,093,507
|
1.65
|
%
|
|||||||
Manufactures finished
|
|||||||||||
watches, movements and
|
|||||||||||
components. Produces
|
|||||||||||
components necessary to
|
|||||||||||
its various watch brand
|
|||||||||||
companies. The company
|
|||||||||||
also operates
|
|||||||||||
retail boutiques.
|
|||||||||||
(Cost $2,466,618)
|
|||||||||||
8,144,716
|
6.42
|
%
|
|||||||||
Semiconductors — 1.11%
|
|||||||||||
562,500
|
ams-OSRAM AG1
|
1,412,850
|
1.11
|
%
|
|||||||
Designs and manufactures
|
|||||||||||
advanced sensor solutions.
|
|||||||||||
The company also delivers
|
|||||||||||
a broad range of
|
|||||||||||
technology solutions for
|
|||||||||||
consumer electronics and
|
|||||||||||
communication device
|
|||||||||||
manufactures.
|
|||||||||||
(Cost $1,958,569)
|
|||||||||||
1,412,850
|
1.11
|
%
|
|||||||||
Transportation — 1.55%
|
|||||||||||
5,720
|
Kuehne + Nagel
|
||||||||||
International AG
|
1,969,531
|
1.55
|
%
|
||||||||
Transports freight
|
|||||||||||
worldwide. The company
|
|||||||||||
operates sea, land, and
|
|||||||||||
rail freight transportation
|
|||||||||||
businesses and warehousing
|
|||||||||||
and distribution facilities.
|
|||||||||||
(Cost $1,558,223)
|
|||||||||||
1,969,531
|
1.55
|
%
|
|||||||||
Total Common Stock
|
|||||||||||
(Cost $84,164,395)
|
124,022,336
|
97.78
|
%
|
See Notes to Financial Statements.
Schedule of Investments by Industry |
December 31, 2023
|
(continued) |
Percent
|
|||||||||||
No. of
|
of Net
|
||||||||||
Shares
|
Security
|
Value
|
Assets
|
||||||||
Preferred Stock — 0.00%
|
|||||||||||
Industrial Goods & Services — 0.00%
|
|||||||||||
500,863
|
SelFrag AG Class A1,2,3
|
$
|
5,178
|
0.00
|
%
|
||||||
Designs, manufactures
|
|||||||||||
and sells industrial
|
|||||||||||
machines and processes
|
|||||||||||
using selective
|
|||||||||||
fragmentation technology.
|
|||||||||||
(Cost $1,932,198)
|
|||||||||||
5,178
|
0.00
|
%
|
|||||||||
Total Preferred Stock
|
|||||||||||
(Cost $1,932,198)
|
5,178
|
0.00
|
%
|
||||||||
Limited Partnership — 0.79%
|
|||||||||||
Biotechnology — 0.79%
|
|||||||||||
3,294,705
|
Aravis Biotech II, Limited
|
||||||||||
Partnership1,3,4
|
997,278
|
0.79
|
%
|
||||||||
Makes early stage venture
|
|||||||||||
investments in the
|
|||||||||||
biotechnology &
|
|||||||||||
pharmaceuticals industry.
|
|||||||||||
(Cost $213,885)
|
|||||||||||
997,278
|
0.79
|
%
|
|||||||||
Total Limited
|
|||||||||||
Partnership
|
|||||||||||
(Cost $213,885)
|
997,278
|
0.79
|
%
|
||||||||
Total Investments5
|
|||||||||||
(Cost $86,310,478)
|
125,024,792
|
98.57
|
%
|
||||||||
Other Assets
|
|||||||||||
Less Liabilities5
|
1,806,464
|
1.43
|
%
|
||||||||
Net Assets
|
$
|
126,831,256
|
100.00
|
%
|
|||||||
Net Asset Value Per Share:
|
|||||||||||
($126,831,256 ÷
|
|||||||||||
shares outstanding,
|
|||||||||||
$0.001 par value:
|
|||||||||||
shares authorized)
|
$
|
|
See Notes to Financial Statements.
Schedule of Investments by Industry
|
December 31, 2023
|
(continued)
|
1
|
Non-income producing security.
|
2
|
Value determined using significant unobservable inputs.
|
3
|
Illiquid. There is not a public market for these securities in the United States or in any foreign jurisdiction, including Switzerland. Securities are priced at Fair Value in accordance with
the Fund’s valuation policy and procedures. Aravis Biotech II, Limited Partnership was valued at net asset value as a practical expedient for fair value. At the end of the period, the aggregate Fair Value of these securities amounted to
$1,346,338 or 1.06% of the Fund’s net assets. Additional information on these securities is as follows:
|
Security
|
Acquisition Date
|
Cost
|
||||
Aravis Biotech II, Limited Partnership
|
July 31, 2007 – May 29, 2018
|
$
|
213,885
|
|||
Eyesense AG – Common Shares
|
July 22, 2010 – October 3, 2011
|
3,007,048
|
||||
SelFrag AG – Class A – Preferred Shares
|
December 15, 2011 – January 28, 2014
|
1,932,198
|
||||
Spineart SA – Common Shares
|
December 22, 2010 - December 20, 2020
|
1,554,486
|
||||
$
|
6,707,617
|
4
|
Affiliated Company. An affiliated company is a company in which the Fund has ownership of at least 5% of the company’s outstanding voting securities or an equivalent interest in the company.
Details related to affiliated company holdings are as follows:
|
Limited Partnership – 0.79% | |
Biotechnology – 0.79%
|
Value
|
Change in
|
Value
|
Shares
|
||||||||||||||||||||||||||||||||||
as of
|
Gross
|
Gross
|
Corporate
|
Realized
|
Unrealized
|
Interest
|
as of
|
as of
|
|||||||||||||||||||||||||||||
Name of Issuer
|
12/31/22
|
Additions
|
Reductions
|
Actions
|
Gain/(Loss)
|
Gain/(Loss)
|
Income
|
12/31/23
|
12/31/23
|
||||||||||||||||||||||||||||
Aravis Biotech II,
|
|||||||||||||||||||||||||||||||||||||
Limited Partnership1,3
|
$
|
1,302,142
|
$
|
—
|
$
|
(1,814,239
|
)
|
$
|
—
|
$
|
217,940
|
$
|
1,291,435
|
$
|
—
|
$
|
997,278
|
3,294,705
|
|||||||||||||||||||
$
|
1,302,142
|
$
|
—
|
$
|
(1,814,239
|
)
|
$
|
—
|
$
|
217,940
|
$
|
1,291,435
|
$
|
—
|
$
|
997,278
|
3,294,705
|
5
|
All of the Fund’s investments and other assets are pledged as collateral in accordance with a credit agreement with U.S. Bank, National Association.
|
See Notes to Financial Statements.
Schedule of Investments by Industry
|
December 31, 2023
|
(concluded)
|
PORTFOLIO HOLDINGS
|
||||
% of Net Assets as of December 31, 2023
|
||||
Pharmaceuticals
|
21.66
|
%
|
||
Food
|
20.70
|
%
|
||
Insurance
|
8.32
|
%
|
||
Healthcare-Products
|
7.30
|
%
|
||
Retail
|
6.42
|
%
|
||
Diversified Financial Services
|
3.27
|
%
|
||
Biotechnology
|
3.07
|
%
|
||
Banks
|
3.03
|
%
|
||
Building Materials
|
2.96
|
%
|
||
Private Equity
|
2.79
|
%
|
||
Electronic Components & Equipment
|
2.73
|
%
|
||
Health Care
|
2.34
|
%
|
||
Computers
|
1.68
|
%
|
||
Packaging & Containers
|
1.63
|
%
|
||
Transportation
|
1.55
|
%
|
||
Electric
|
1.54
|
%
|
||
Industrials
|
1.38
|
%
|
||
Chemicals
|
1.34
|
%
|
||
Advertising
|
1.15
|
%
|
||
Semiconductors
|
1.11
|
%
|
||
Metal Fabricate/Hardware
|
1.07
|
%
|
||
Healthcare - Services
|
0.77
|
%
|
||
Machinery-Diversified
|
0.76
|
%
|
||
Industrial Goods & Services
|
0.00
|
%
|
||
Other Assets Less Liabilities
|
1.43
|
%
|
||
100.00
|
%
|
|||
TOP 10 PORTFOLIO HOLDINGS
|
||||
% of Net Assets as of December 31, 2023
|
||||
Nestle SA
|
17.71
|
%
|
||
Novartis AG
|
11.31
|
%
|
||
Roche Holding AG
|
10.35
|
%
|
||
Cie Financiere Richemont SA
|
4.77
|
%
|
||
Zurich Insurance Group AG
|
4.32
|
%
|
||
UBS Group AG
|
2.84
|
%
|
||
Partners Group Holding AG
|
2.79
|
%
|
||
Sika AG
|
2.15
|
%
|
||
Alcon, Inc.
|
2.09
|
%
|
||
Tecan Group AG
|
1.86
|
%
|
See Notes to Financial Statements.
Statement of Assets and Liabilities
|
December 31, 2023
|
Assets:
|
||||
Investments in unaffiliated issuers, at value (cost $86,096,593)
|
$
|
124,027,514
|
||
Investments in affiliated issuers, at value (cost $213,885)
|
997,278
|
|||
Total Investments, at value (cost $86,310,478)
|
125,024,792
|
|||
Cash and cash equivalents
|
669,256
|
|||
Foreign currency (cost $23,330)
|
23,446
|
|||
Tax reclaims receivable
|
1,431,019
|
|||
Interest receivable
|
449
|
|||
Prepaid expenses
|
19,919
|
|||
Total assets
|
127,168,881
|
|||
Liabilities:
|
||||
Accrued Fees and Expenses:
|
||||
Investment advisory
|
76,679
|
|||
Directors
|
76,567
|
|||
Legal
|
19,484
|
|||
Audit
|
55,505
|
|||
Custody
|
8,786
|
|||
Credit facility interest
|
32,313
|
|||
Other
|
68,291
|
|||
Total liabilities
|
337,625
|
|||
Net assets
|
$
|
126,831,256
|
||
Composition of Net Assets:
|
||||
Paid-in capital
|
88,205,751
|
|||
Total distributable earnings
|
38,625,505
|
|||
Net assets
|
$
|
126,831,256
|
||
Net Asset Value Per Share:
|
||||
($126,831,256 ÷
shares outstanding, |
||||
$0.001 par value:
shares authorized) |
$
|
|
See Notes to Financial Statements.
Statement of Operations
|
For the Year Ended December 31, 2023
|
Investment Income:
|
||||
Dividend (less of foreign tax withheld of $489,651)
|
$
|
2,912,736
|
||
Interest income
|
30,945
|
|||
Total income
|
2,943,681
|
|||
Expenses:
|
||||
Investment advisory fees (Note 2)
|
861,972
|
|||
Directors’
|
309,335
|
|||
Legal (Note 3)
|
137,839
|
|||
Officers
|
136,129
|
|||
Administration (Note 3)
|
130,133
|
|||
Delaware franchise tax (Note 9)
|
81,200
|
|||
Credit facility interest
|
69,508
|
|||
Printing and shareholder reports
|
63,086
|
|||
Audit (Note 3)
|
55,505
|
|||
Custody (Note 3)
|
58,059
|
|||
Insurance
|
48,465
|
|||
Transfer agency (Note 3)
|
36,477
|
|||
Miscellaneous
|
59,670
|
|||
Total expenses
|
2,047,378
|
|||
Net investment income
|
896,303
|
|||
Realized and Unrealized Gains on Investments and Foreign Currency Translations:
|
||||
Net realized gain from:
|
||||
Investments in unaffiliated issuers
|
3,634,014
|
|||
Investments in affiliated issuers
|
217,940 |
|||
Foreign currency transactions
|
205,218
|
|||
Total net realized gain from unaffiliated and
|
||||
affiliated issuers and foreign currency transactions
|
4,057,172
|
|||
Net change in unrealized appreciation from:
|
||||
Investments in unaffiliated issuers
|
12,473,373
|
|||
Investments in affiliated issuers
|
1,291,435
|
|||
Foreign currency translations
|
114,814
|
|||
Total net change in unrealized appreciation from
|
||||
unaffiliated and affiliated issuers, and foreign currency translations
|
13,879,622
|
|||
Net Realized and Unrealized Gain on
|
||||
Investments and Foreign Currency Translations
|
17,936,794
|
|||
Net Increase in Net Assets from Operations
|
$
|
18,833,097
|
See Notes to Financial Statements.
Statement of Cash Flows
|
For the Year Ended December 31, 2023
|
Cash flows from operating activities:
|
||||
Net increase in net assets applicable to common shareholders
|
$
|
18,833,097
|
||
Adjustments to reconcile net increase in net assets applicable to
|
||||
common shareholders resulting from operations to net cash
|
||||
provided by operating activities:
|
||||
Purchases of investments
|
(16,922,326
|
)
|
||
Proceeds from sales of investments
|
22,216,493
|
|||
Net purchases and sales of short-term investments
|
331,030
|
|
||
Return of capital distributions received from underlying investments
|
1,603,806
|
|||
Increase in tax reclaims receivable
|
(133,131
|
)
|
||
Decrease in dividends and interest receivable
|
2,498
|
|||
Decrease in other assets
|
517
|
|||
Increase in payable to Adviser
|
6,422
|
|||
Increase in accrued expenses and other liabilities
|
6,788
|
|||
Net realized gains from investments
|
(3,851,954
|
)
|
||
Net change in unrealized appreciation (depreciation) from investments
|
(13,764,808
|
)
|
||
Net cash provided by operating activities
|
8,328,432
|
|||
Cash flows from financing activities:
|
||||
Distributions paid to common shareholders
|
(6,488,430
|
)
|
||
Repurchase of common stock
|
(1,687,724
|
)
|
||
Net cash used in financing activities
|
(8,176,154
|
)
|
||
Net change in cash
|
$
|
152,278
|
|
|
Cash:
|
||||
Beginning of year*
|
540,424
|
|||
End of year*
|
$
|
692,702
|
||
Cash financing activities not included herein consist of interest paid
|
44,506
|
*
|
Cash included in the Statement of Cash Flows comprise of foreign currency and Money Market Deposit Account.
|
See Notes to Financial Statements.
For the
|
For the
|
|||||||
Year Ended
|
Year Ended
|
|||||||
December 31, 2023
|
December 31, 2022
|
|||||||
Increase (Decrease) in Net Assets:
|
||||||||
Operations:
|
||||||||
Net investment income
|
$
|
896,303
|
$
|
920,814
|
||||
Total net realized gain from unaffiliated and
|
||||||||
affiliated issuers and foreign currency transactions
|
4,057,172
|
2,080,182
|
||||||
Total net change in unrealized appreciation
|
||||||||
(depreciation) from unaffiliated and affiliated issuers,
|
||||||||
foreign currency and foreign currency translations
|
13,879,622
|
(30,399,182
|
)
|
|||||
Net increase (decrease) in net assets from operations
|
18,833,097
|
(27,398,186
|
)
|
|||||
Distributions to Stockholders:
|
||||||||
From earnings
|
(5,796,462
|
)
|
(2,977,194
|
)
|
||||
From return of capital
|
(691,968
|
)
|
(5,241,653
|
)
|
||||
Total distributions to stockholders
|
(6,488,430
|
)
|
(8,218,847
|
)
|
||||
Capital Stock Transactions:
|
||||||||
Value of shares repurchased through
|
||||||||
stock repurchase program (Note 6)
|
(1,687,724
|
)
|
(120,928
|
)
|
||||
Total decrease from capital share transactions
|
(1,687,724
|
)
|
(120,928
|
)
|
||||
Total increase (decrease) in net assets
|
10,656,943
|
(35,737,961
|
)
|
|||||
Net Assets:
|
||||||||
Beginning of year
|
116,174,313
|
151,912,274
|
||||||
End of year
|
$
|
126,831,256
|
$
|
116,174,313
|
See Notes to Financial Statements.
For the Years Ended December 31,
|
||||||||||||||||||||
2023
|
2022
|
2021
|
2020
|
2019
|
||||||||||||||||
Per Share Operating Performance:
|
||||||||||||||||||||
Net asset value at the beginning of year
|
$
|
8.80
|
$
|
11.50
|
$
|
10.45
|
$
|
9.71
|
$
|
7.96
|
||||||||||
Income from Investment Operations:
|
||||||||||||||||||||
Net investment income1
|
0.07
|
0.07
|
0.05
|
0.05
|
0.01
|
|||||||||||||||
Net realized and unrealized
|
||||||||||||||||||||
gain (loss) on investments2
|
1.36
|
(2.15
|
)
|
1.58
|
1.24
|
1.88
|
||||||||||||||
Total from investment activities
|
1.43
|
(2.08
|
)
|
1.63
|
1.29
|
1.89
|
||||||||||||||
Anti-dilutive effect of common
|
||||||||||||||||||||
share repurchase program
|
0.03
|
0.00
|
4
|
—
|
0.01
|
—
|
||||||||||||||
Less Distributions:
|
||||||||||||||||||||
Net investment income
|
(0.17
|
)
|
(0.06
|
)
|
(0.06
|
)
|
(0.08
|
)
|
(0.12
|
)
|
||||||||||
Net realized gains
|
(0.28
|
)
|
(0.16
|
)
|
(0.09
|
)
|
—
|
(0.02
|
)
|
|||||||||||
Return of Capital
|
(0.05
|
)
|
(0.40
|
)
|
(0.43
|
)
|
(0.48
|
)
|
—
|
|||||||||||
Total distributions
|
(0.50
|
)
|
(0.62
|
)
|
(0.58
|
)
|
(0.56
|
)
|
(0.14
|
)
|
||||||||||
Net asset value at end of year
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||
Market value per share at the end of year
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||
Total Investment Returns:3
|
||||||||||||||||||||
Based on market value per share
|
15.48
|
%
|
-17.62
|
%
|
18.25
|
%
|
14.18
|
%
|
24.00
|
%
|
||||||||||
Based on net asset value per share
|
16.92
|
%
|
-17.97
|
%
|
16.09
|
%
|
14.29
|
%
|
23.80
|
%
|
||||||||||
Ratios to Average Net Assets:
|
||||||||||||||||||||
Net expenses
|
1.66
|
%6
|
1.68
|
%5
|
1.40
|
%
|
1.80
|
%
|
2.13
|
%
|
||||||||||
Gross expenses
|
1.66
|
%6
|
1.68
|
%5
|
1.40
|
%
|
1.80
|
%
|
2.13
|
%
|
||||||||||
Net investment income
|
0.73
|
%
|
0.74
|
%
|
0.48
|
%
|
0.48
|
%
|
0.10
|
%
|
||||||||||
Supplemental Data and Ratios
|
||||||||||||||||||||
Net assets at end of year (000’s)
|
$
|
126,831
|
$
|
116,174
|
$
|
151,912
|
$
|
138,040
|
$
|
128,864
|
||||||||||
Average net assets during the year (000’s)
|
$
|
123,139
|
$
|
123,684
|
$
|
144,019
|
$
|
125,666
|
$
|
118,960
|
||||||||||
Portfolio turnover rate
|
14
|
%
|
15
|
%
|
11
|
%
|
12
|
%
|
18
|
%
|
1
|
Calculated using the average shares method.
|
2
|
Includes net realized and unrealized currency gains and losses.
|
3
|
Total investment return based on market value differs from total investments return based on net asset value due to changes in the relationship between the market value of the Fund’s shares
and its NAV per share.
|
4
|
Less than 0.5 cents per share.
|
5
|
If interest expense and commitment fees had been excluded, the expense ratios would have been lower by 0.05% for the year ended December 31, 2022.
|
6 |
If interest expense and commitment fees had been excluded, the expense ratios would have been lower by 0.06% for the year ended December 31, 2023.
|
See Notes to Financial Statements.
Level 1—
|
unadjusted quoted prices in active markets for identical assets and liabilities
|
Level 2—
|
other significant observable inputs (including quoted prices of similar securities, interest rates, prepayment speeds, credit risk, etc.)
|
Level 3—
|
significant unobservable inputs (including the Fund’s own assumptions in determining the fair value of investments)
|
Level 2
|
Level 3
|
Investments
|
||||||||||||||||||
Level 1
|
Other Significant
|
Significant
|
Valued at
|
|||||||||||||||||
Quoted Prices
|
Observable Inputs
|
Unobservable Inputs
|
NAV**
|
Total
|
||||||||||||||||
Investments in Securities*
|
||||||||||||||||||||
Common Stock
|
$
|
122,681,176
|
$
|
—
|
$
|
1,341,160
|
$
|
—
|
$
|
124,022,336
|
||||||||||
Preferred Stock
|
—
|
—
|
5,178
|
—
|
5,178
|
|||||||||||||||
Limited Partnership
|
—
|
—
|
—
|
997,278
|
997,278
|
|||||||||||||||
Total Investments in Securities
|
$
|
122,681,176
|
$
|
—
|
$
|
1,346,338
|
$
|
997,278
|
$
|
125,024,792
|
*
|
Please see the Schedule of Investments for industry classifications.
|
**
|
As of December 31, 2023, certain of the Fund’s investments were valued using net asset value (“NAV”) per share (or its equivalent) as a practical expedient for fair value and have been
excluded from the fair value hierarchy in accordance with ASU 2015-07. The fair value amount presented in this table is intended to permit reconciliation of the amounts presented in the fair value hierarchy to the amounts presented in the
statement of assets and liabilities.
|
Value at
|
||||||||||
December 31, 2023
|
Valuation Technique
|
Unobservable Inputs
|
Range1
|
|||||||
Healthcare-Products
|
||||||||||
EyeSense AG, Series A—Common Shares
|
$
|
1,490
|
Market approach
|
Based on expected sale
|
N/A
|
|||||
proceeds due to sale back
|
||||||||||
of shares of Eyesense
|
||||||||||
Spineart SA—Common Shares
|
1,339,670
|
Market approach
|
Based on listed trading
|
15-25
|
%
|
|||||
multiples, cross checked to
|
||||||||||
secondary share purchase
|
||||||||||
with additional discount for
|
||||||||||
lack of marketability
|
||||||||||
Industrial Goods & Services
|
||||||||||
SelFrag AG Class A—Preferred Shares
|
5,178
|
Market approach
|
Based on expected sale
|
N/A
|
||||||
proceeds due to sale back
|
||||||||||
of shares of Selfrag
|
||||||||||
Total
|
$
|
1,346,338
|
1
|
Significant changes in any of these ranges would result in a significantly higher or lower fair value measurement. A change in the discount rate is accompanied by a directionally opposite
change in fair value.
|
Common
|
Preferred
|
|||||||||||
Stock
|
Stock
|
Total
|
||||||||||
Balance as of December 31, 2022
|
$
|
1,384,260
|
$
|
48,722
|
$
|
1,432,982
|
||||||
Change in Unrealized Appreciation/Depreciation
|
(43,100
|
)
|
(43,544
|
)
|
(86,644
|
)
|
||||||
Net Realized Gain (Loss)
|
—
|
—
|
—
|
|||||||||
Gross Purchases
|
—
|
—
|
—
|
|||||||||
Gross Sales
|
—
|
—
|
—
|
|||||||||
Transfer out of Level 3
|
—
|
—
|
—
|
|||||||||
Balance as of December 31, 2023
|
$
|
1,341,160
|
$
|
5,178
|
$
|
1,346,338
|
||||||
Change in unrealized appreciation (depreciation) during the period
|
||||||||||||
for Level 3 investments held at December 31, 2023
|
(43,100
|
)
|
(43,544
|
)
|
(86,644
|
)
|
For the Year Ended
|
For the Year Ended
|
|||||||||||||||
December 31, 2023
|
December 31, 2022
|
|||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
|||||||||||||
Dividends Reinvested
|
—
|
$
|
—
|
—
|
$
|
—
|
||||||||||
Repurchased through Stock Repurchase Program (Note 6)
|
(205,045
|
)
|
(1,687,724
|
)
|
(16,504
|
)
|
(120,928
|
)
|
||||||||
Repurchased from Tender Offer (Note 7)
|
—
|
—
|
—
|
—
|
||||||||||||
Net Increase/(Decrease)
|
(205,045
|
)
|
$
|
(1,687,724
|
)
|
(16,504
|
)
|
$
|
(120,928
|
)
|
2023
|
2022
|
|||||||
Ordinary Income
|
$
|
2,489,577
|
$
|
810,137
|
||||
Return of Capital
|
691,968
|
5,241,653
|
||||||
Long-Term Capital Gains
|
3,306,885
|
2,167,057
|
||||||
Total
|
$
|
6,488,430
|
$
|
8,218,847
|
Tax cost of investments
|
$
|
86,488,037
|
||
Unrealized appreciation
|
48,523,318
|
|||
Unrealized depreciation
|
(9,986,563
|
)
|
||
Net unrealized appreciation
|
38,536,755
|
|||
Net unrealized on foreign currency
|
119,189
|
|||
Undistributed ordinary income
|
—
|
|||
Undistributed long-term capital gains
|
—
|
|||
Distributable earnings
|
—
|
|||
Other accumulated losses
|
(30,439
|
)
|
||
Total distributable earnings
|
$
|
38,625,505
|
Record Date
|
Payable Date
|
Ordinary Income
|
Return of Capital
|
ST Cap Gains
|
LT Cap Gains
|
Total Distribution
|
|||||||||||||||
3/22/23
|
3/31/23
|
$
|
0.04139848
|
$
|
0.01310152
|
$
|
0.00574
|
$
|
0.06261
|
$
|
0.12285
|
||||||||||
6/21/23
|
6/30/23
|
0.04139848
|
0.01310152
|
0.00574
|
0.06261
|
0.12285
|
|||||||||||||||
9/20/23
|
9/29/23
|
0.04139848
|
0.01310152
|
0.00574
|
0.06261
|
0.12285
|
|||||||||||||||
12/19/23
|
12/29/23
|
0.04346261
|
0.01375739
|
0.00603
|
0.06575
|
0.12900
|
|||||||||||||||
$
|
0.49755
|
Original Capital
|
Unfunded
|
|||||||
Investments
|
Commitment*
|
Commitment*
|
||||||
Private Equity Limited Partnership—International(a)
|
||||||||
Aravis Biotech II, Limited Partnership
|
$
|
3,861,463
|
$
|
—
|
*
|
The original capital commitment represents 3,250,000 Swiss francs, which has been fully funded as of December 31, 2023. The Swiss franc/U.S. dollar exchange rate as of December 31, 2023 was
used for conversion and equaled 0.84165 as of such date.
|
(a)
|
This category consists of one private equity limited partnership that invests primarily in venture capital companies in the biotechnology and medical technology sectors. There is no
redemption right for the interest in this limited partnership. Instead, the nature of investments in this category is that distributions are received through the realization of the underlying assets of the limited partnership.
|
Weighted
|
|||||
Maximum Amount
|
Average Daily
|
Maximum Amount
|
Interest
|
Commitment
|
Average
|
Available
|
Borrowings
|
Outstanding
|
Expense
|
Fee
|
Interest Rate
|
$15,000,000
|
$319,203
|
$4,811,000
|
$21,036
|
$48,472
|
6.50%
|
Fund Investment Objective, Principal Investment
|
December 31, 2023
|
Fund Investment Objective, Principal Investment
|
December 31, 2023
|
Fund Investment Objective, Principal Investment
|
December 31, 2023
|
Fund Investment Objective, Principal Investment
|
December 31, 2023
|
Fund Investment Objective, Principal Investment
|
December 31, 2023
|
Fund Investment Objective, Principal Investment
|
December 31, 2023
|
Fund Investment Objective, Principal Investment
|
December 31, 2023
|
Fund Investment Objective, Principal Investment
|
December 31, 2023
|
Fund Investment Objective, Principal Investment
|
December 31, 2023
|
Gross Foreign
|
Foreign Taxes
|
Gross Foreign
|
Foreign Taxes
|
Shares Outstanding
|
Source Income
|
Pass-through
|
Source Income Per Share
|
Pass-through Per Share
|
at 12/31/23
|
3,402,387
|
489,651
|
0.26190932
|
0.03769238
|
12,990,705
|
Position(s)
|
Other Directorships
|
||
Name,
|
with Fund
|
Principal Occupation(s)
|
Held By Director
|
Address1 & Age
|
(Since)
|
During At Least The Past Five Years
|
During At Least The Past Five Years
|
Class I
|
|||
Richard Dayan
|
Director (2018);
|
President and owner of
|
Trustee of High Income Securities
|
Member of the
|
Cactus Trading since 1990
|
Fund since 2018
|
|
Age: 80
|
Audit Committee (2018);
|
||
Member of the
|
|||
Governance/
|
|||
Nominating
|
|||
Committee (2018)
|
|||
Moritz A. Sell
|
Director (2017);
|
Principal, Edison Holdings GmbH;
|
Trustee of High Income Securities
|
Member and
|
Senior Advisor, Markston
|
Fund since 2018; Director of FAX
|
|
Age: 56
|
Chair of the Audit
|
International LLC until 2019; Director,
|
(Aberdeen Asia Pacific Income
|
Committee (2017);
|
Market Strategist and Head of
|
Fund) and FCO (Aberdeen Global
|
|
Lead Independent
|
Proprietary Trading (London Branch),
|
Income Fund) since 2018; Director of
|
|
Director (2018)
|
Landesbank Berlin AG and
|
IAF (Aberdeen Australia Equity Fund)
|
|
Landesbank Berlin Holding AG
|
since 2004; Director of Aberdeen
|
||
(formerly, Bankgesellschaft Berlin AG)
|
Greater China Fund until 2018;
|
||
from 1996 to 2013
|
Chairman and Director of
|
||
Aberdeen Singapore Fund
|
|||
until 2018
|
|||
Class II
|
|||
Andrew Dakos*
|
Director
|
Partner, Bulldog Investors, LLP;
|
President and Director of Special
|
(2017) and
|
Partner, Ryan Heritage, LLP;
|
Opportunities Fund, Inc. since
|
|
Age: 57
|
Chairman (2018)
|
Principal of the former general partner
|
2009; Trustee, Crossroads
|
of several private investment
|
Liquidating Trust (formerly,
|
||
partnerships in the Bulldog
|
Crossroads Capital, Inc.) from
|
||
Investors group of private funds;
|
2015-2020; President and Trustee of
|
||
Principal of the managing general
|
High Income Securities Fund since
|
||
partner of Bulldog Investors
|
2018; Director, Brookfield DTLA
|
||
General Partnership
|
Fund Office Trust Investor Inc.
|
||
since 2017
|
*
|
Mr. Dakos is considered an “interested person” of the Fund within the meaning of the 1940 Act (and a Class II Interested Director of the Fund) as a result of his position as President and
Chief Executive Officer of the Fund.
|
Position(s)
|
Other Directorships
|
||
Name,
|
with Fund
|
Principal Occupation(s)
|
Held By Director
|
Address1 & Age
|
(Since)
|
During At Least The Past Five Years
|
During At Least The Past Five Years
|
Class III
|
|||
Phillip F. Goldstein
|
Director (2018);
|
Partner of Bulldog Investors, LLP
|
Chairman and Director of The
|
Member and
|
since 2009; Partner of Ryan
|
Mexico Equity and Income Fund,
|
|
Age: 79
|
Chair of the
|
Heritage, LLP; Principal of the former
|
Inc. since 2000; Chairman,
|
Governance/
|
general partner of several private
|
Director and Secretary of Special
|
|
Nominating
|
investment partnerships in the
|
Opportunities Fund, Inc. since
|
|
Committee (2018)
|
Bulldog Investors group of private
|
2009; Chairman, Trustee and Secretary
|
|
funds since 2009; Principal of the
|
of High Income Securities Fund since
|
||
managing general partner of
|
2018; Director of Brookfield DTLA
|
||
Bulldog Investors General Partnership
|
Fund Office Trust Investor Inc.
|
||
since 2017; MVC Capital, Inc. from
|
|||
2012-2020; Trustee of Crossroads
|
|||
Liquidating Trust (formerly,
|
|||
Crossroads Capital, Inc.) from
|
|||
2016-2020
|
|||
Gerald Hellerman
|
Director (2018);
|
Chief Compliance Officer of
|
Director of Mexico Equity and
|
Member of the
|
The Mexico Equity and Income Fund,
|
Income Fund, Inc. since 2001;
|
|
Age: 86
|
Audit Committee
|
Inc. from 2001 through March 31,
|
Special Opportunities Fund, Inc.
|
(2018); Member
|
2020 and Special Opportunities
|
since 2009; Fiera Capital Series Trust
|
|
and Chair of the
|
Fund, Inc. from 2009 through
|
from 2017-2023; Trustee of High
|
|
Pricing Committee
|
March 31, 2020; Managing Director
|
Income Securities Fund since 2018;
|
|
(2018)
|
of Hellerman Associates (a financial
|
MVC Capital, Inc. from
|
|
and corporate consulting firm)
|
2003-2020; Trustee of Crossroads
|
||
since 1993 (which terminated
|
Liquidating Trust (formerly, Crossroads
|
||
activities as of December 31, 2013)
|
Capital, Inc.) from 2017-2020
|
Officers2
|
|||
Name,
|
Position(s)
|
Term of Office and
|
Principal Occupation(s)
|
Address1 & Age
|
with Fund
|
Length of Time Served
|
During At Least The Past Five Years
|
Andrew Dakos
|
President and
|
President and Chief
|
Partner, Bulldog Investors, LLP;
|
Chief Executive
|
Executive Officer since 2019;
|
Partner, Ryan Heritage, LLP;
|
|
Age: 57
|
Officer; Director
|
Chairman since 2018;
|
Principal of the former general
|
and Chairman.
|
Director since 2017
|
partner of several private
|
|
investment partnerships in the
|
|||
Bulldog Investors group of private
|
|||
funds; Principal of the managing
|
|||
general partner of Bulldog
|
|||
Investors General Partnership
|
|||
Thomas Antonucci
|
Chief Financial
|
Since 2019
|
Director of Operations,
|
Officer
|
Bulldog Investors, LLP;
|
||
Age: 55
|
Chief Financial Officer
|
||
and Treasurer of Special
|
|||
Opportunities Fund; Treasurer
|
|||
of High Income Securities Fund
|
|||
Stephanie Darling
|
Chief Compliance
|
Since 2019
|
General Counsel and Chief
|
Officer
|
Compliance Officer of Bulldog
|
||
Age: 53
|
Investors, LLP; Chief Compliance
|
||
Officer of Ryan Heritage, LLP,
|
|||
High Income Securities
|
|||
Fund, Special Opportunities Fund,
|
|||
Inc., and Mexico Equity and
|
|||
Income Fund, Inc.; Principal of The
|
|||
Law Office of Stephanie Darling;
|
|||
Editor-in-Chief of The
|
|||
Investment Lawyer
|
|||
Rajeev Das
|
Secretary
|
Since 2019
|
Head of Trading, Bulldog
|
Investors, LLP
|
|||
Age: 55
|
1
|
The address for each Director and Executive Officer is c/o The Swiss Helvetia Fund, Inc., 615 East Michigan Street, Milwaukee, WI 53202.
|
||
2
|
Each Executive Officer serves on a year-to-year basis for an indefinite term, until his or her successor is elected and qualified.
|
Andrew Dakos
|
Gerald Hellerman1,4
|
Chairman, President and
|
Director
|
Chief Executive Officer
|
Thomas Antonucci
|
Richard Dayan1,5
|
Chief Financial Officer
|
Director
|
Stephanie Darling
|
Phillip Goldstein2
|
Chief Compliance Officer
|
Director
|
Rajeev Das
|
Moritz Sell3,6
|
Secretary
|
Director
|
1
|
Audit Committee Member
|
4
|
Pricing Committee Chair
|
2
|
Governance Nominating
|
5
|
Governance Committee
|
Committee Chair
|
Member
|
||
3
|
Audit Committee Chair
|
6
|
Lead Independent Director
|
Number of
Accounts
|
Total Assets in
Accounts
|
Number of Accounts
where Advisory Fee
is Based on Account
Performance
|
Total Assets in
Accounts where
Advisory Fee is
Based on Account
Performance
|
|
Stefan
Frischknecht
|
|
|
|
|
Registered
Investment
Companies
|
None
|
None
|
None
|
None
|
Other Pooled
Investment
Vehicles
|
2
|
$60,007,941
|
None
|
None
|
Other Accounts
|
3
|
$997,967,010
|
None
|
None
|
Daniel Lenz
|
|
|
|
|
Registered
Investment
Companies
|
None
|
None
|
None
|
None
|
Other Pooled
Investment
Vehicles
|
4
|
$784,850,126
|
None
|
None
|
Other Accounts
|
4
|
$829,364,023
|
None
|
None
|
Period
|
(a)
Total Number of
Shares (or Units)
Purchased
|
(b)
Average Price Paid
per Share (or Unit)
|
(c)
Total Number of
Shares (or Units)
Purchased as Part
of Publicly
Announced Plans
or Programs
|
(d)
Maximum Number
(or Approximate
Dollar Value) of
Shares (or Units)
that May Yet Be
Purchased Under
the Plans or
Programs
|
7/1/23 – 7/31/23
|
N/A
|
N/A
|
N/A
|
N/A
|
8/1/23 – 8/31/23
|
N/A
|
N/A
|
N/A
|
N/A
|
9/1/23 – 9/30/23
|
N/A
|
N/A
|
N/A
|
N/A
|
10/1/23 – 10/31/23
|
N/A
|
N/A
|
N/A
|
N/A
|
11/1/23 – 11/30/23
|
N/A
|
N/A
|
N/A
|
N/A
|
12/1/23 – 12/31/23
|
N/A
|
N/A
|
N/A
|
N/A
|
Total
|
(a)
|
The Registrant’s President and Chief Executive Officer and Chief Financial Officer have reviewed the Registrant's disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940 (the “Act”)) as
of a date within 90 days of the filing of this report, as required by Rule 30a-3(b) under the Act and Rules 13a-15(b) or 15d‑15(b) under the Securities Exchange Act of 1934. Based on their review, such officers have concluded that the
disclosure controls and procedures are effective in ensuring that information required to be disclosed in this report is appropriately recorded, processed, summarized and reported and made known to them by others within the Registrant and
by the Registrant’s service provider.
|
(b)
|
There were no changes in the Registrant's internal control over financial reporting (as defined in Rule 30a-3(d) under the Act) that occurred during the period covered by this report that have materially affected, or are reasonably
likely to materially affect, the Registrant's internal control over financial reporting.
|